FIELD: biotechnology.
SUBSTANCE: invention relates to modified version of peptide FGF21, and can be used in medicine. Invention enables to obtain conjugate of FGF21 protein derivative containing cysteine residue in position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and especially to position 180 or position 181 of mature human FGF21, and a side chain comprising a linker sequence and a protractor.
EFFECT: invention can be used as a metabolic regulator of energy consumption, glucose and lipid metabolism.
17 cl, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| INSULIN CONJUGATES | 2019 |
|
RU2809189C2 |
| ANTIBODIES TO B7-H3 AND CONJUGATES OF ANTIBODY AND DRUG | 2017 |
|
RU2764651C2 |
| SELECTIVE COMPOUNDS OF YY PEPTIDE AND USE THEREOF | 2016 |
|
RU2726777C2 |
| ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
| POLYPEPTIDES | 2012 |
|
RU2669999C2 |
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
